https://www.selleckchem.com/pr....oducts/BAY-73-4506.h
Cardiovascular disease (CVD) is one of the most serious health-related problems in patients with type 2 diabetes, especially in western countries. Basic and clinical research on how to prevent CVD onset and progression in patients with type 2 diabetes have been an urgent task for decades. Glucagon-like peptide-1 (GLP-1) is one of two incretins that are responsible for ≥50% of postprandial insulin secretion and subsequent glucose excursion, and has been intensively investigated from the perspective of CVD due to its cardiovascular be
Like
Comment
Share
